Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: November 26, 2022

Details for Patent: 7,858,662

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,858,662 protect, and when does it expire?

Patent 7,858,662 protects VEREGEN and is included in one NDA.

This patent has thirty-one patent family members in twenty countries.

Summary for Patent: 7,858,662
Title:Medicament for the treatment of viral skin and tumour diseases
Abstract: The invention relates to a medicament containing a compound of general formula (1), where R.sub.1=independently, a straight or branched, saturated, singly- or multiply-unsaturated, optionally substituted C.sub.11-C.sub.21 alkyl, alkylene or alkynyl group, preferably a C.sub.11-C.sub.15 alkyl, alkylene or alkynyl group, particularly a C.sub.11-C.sub.13 alkyl, alkylene or alkynyl group, most preferably a C.sub.13 alkyl group, R2=independently, a straight or branched C.sub.1-C.sub.8 alkyl, alkylene or alkynyl group, preferably a C.sub.1-C.sub.6 alkyl, alkylene or alkynyl group, in particular a C.sub.2-C.sub.4 alkyl, alkylene or alkynyl group, most preferably a C.sub.3 alkyl group, a --[CH.sub.2--(CH.sub.2).sub.m--O].sub.nH group with n=1 to 10, preferably n=1 to 5, m=1 to 5, preferably m=1 to 3, a --CH.sub.2--[CH--(OH)].sub.p[CH.sub.2--(R.sub.3)]-- group, where R.sub.3=independent H or OH, p=1 to 7, preferably p=1 to 4, a pentose group or a hexose group, as therapeutically active agent, alone or in combination with one or several further pharmaceutical agents as a combination preparation for the treatment of viral skin diseases and/or tumor diseases, in particular caused by human papilloma virus (HPV) and/or herpes viruses and a topically acting medicament formulation and the use thereof. ##STR00001##
Inventor(s): Chang; Yunik (Sonoma, CA), Lathrop; Robert (Fort Collins, CO), Bohm; Erwin (Ladenburg, DE), Gander-Meisterernst; Irene (Stockdorf, DE), Greger; Regina (Iffeldorf, DE), Holldack; Johanna (Ebeltoft, DK), Moebius; Ulrich (Gauting-Unterbrunn, DE)
Assignee: MediGene AG (Planegg, DE)
Application Number:10/495,889
Patent Claim Types:
see list of patent claims
Compound; Formulation; Use;

Drugs Protected by US Patent 7,858,662

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Ani Pharms VEREGEN sinecatechins OINTMENT;TOPICAL 021902-001 Oct 31, 2006 RX Yes Yes See Plans and Pricing See Plans and Pricing Y TREATMENT OF GENITAL WARTS See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,858,662

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany101 56 794Nov 19, 2001
PCT Information
PCT FiledNovember 18, 2002PCT Application Number:PCT/EP02/12919
PCT Publication Date:May 30, 2003PCT Publication Number: WO03/043628

International Family Members for US Patent 7,858,662

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 037526 See Plans and Pricing
Austria 417611 See Plans and Pricing
Australia 2002356673 See Plans and Pricing
Brazil 0214256 See Plans and Pricing
Brazil PI0214256 See Plans and Pricing
Canada 2466720 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.